April 26, 2024 07:00 AM EDT

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ UCB is shaking up its leadership team “to better align with its commitment to growth and innovation, and to better address the dynamic external …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Senior Editor

Editor

Sign up to read this article for free.

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs